brainQr Therapeutics is developing next-generation therapies for major human diseases by targeting disordered proteins, a vast and previously largely undruggable class of biomolecules. Our mission is toharness cutting-edge scientific innovation to pioneer novel treatment strategies that address urgent unmet medical needs.

brainQr's lead program focuses on a first-in-class small molecule designed to stabilize the native structure of Tau protein. This groundbreaking approach aims to prevent tau aggregation at its earliest stage, effectively stopping Alzheimer’s disease progression before irreversible neuronal damage occurs.